More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we’ll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We’ll also discuss two FDA approvals that occurred over the past week for lymphoma and kidney cancer.

Coverage of stories discussed this week on ascopost.com:

Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic

FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.